openPR Logo
Press release

Insight into the Latest Developments in Oligonucleotide Delivery Systems

10-29-2019 11:37 AM CET | Health & Medicine

Press release from: SMi Group

RNA Therapeutics Conference & Oligonucleotide Delivery Systems Focus Day

RNA Therapeutics Conference & Oligonucleotide Delivery Systems Focus Day

SMi Group are proud to present the new RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems. The Focus Day will be held on the 18th of February 2020 and will present sessions that showcase a myriad of delivery approaches such as: optimising nanoparticle delivery to treat cancer and fibrosis; a review of common NA-LNP tolerability concerns to improve safety of nucleic acid therapeutics and the utility of light-triggered liposomes for retinal delivery.

In addition to this, delegates will have the opportunity to network with Global Product Managers, Heads of Drug Development, Senior Directors, Heads of Research and Development and many more.

As the only RNA therapeutics conference to dedicate a focus day to exploring developments and innovations in oligonucleotide delivery systems, the Oligonucleotide Delivery Systems Focus Day is a key diary date for those in the industry.

An early bird savings of £400 is available to those who register by 31st October. Register now at: www.therapeutics-rna.com/openPR3

Focus Day Highlights:
Optimising Nanoparticle mediated delivery of siRNAs to treat cancer and fibrosis
• Presenting a polypeptide nanoparticle mediated delivery system for siRNA therapeutics to treat cancer and fibrosis
• The benefits of the ability to deliver multiple siRNAs within the tumour microenvironment
• Leveraging this capability to improve outcomes with Immune Checkpoint inhibitors
• Improved GMP manufacturing approaches using microfluidics for clinical development
David Evans, CSO, Sirnaomics

Addressing the challenge of chronic dosing via traditional LNPbased delivery for mRNA therapeutics
• Clinical appeal of lipid nanoparticle delivery systems and other competing modes of delivery
• Challenges in production and screening of LNP candidates for effective translation to biotherapeutics
• Complications of chronic dosing and acceptable tolerability profiles
• Showcasing the development of a tolerable subcutaneous administration of mRNA via functionalised LNPs
Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca

Exploring the development and progress of BioNTech mRNA therapeutic delivery platforms
• BioNtech’s approach to mRNA therapeutic delivery
• The mRNA oncology delivery platform
• Targeting the immune system via modified mRNA-encoding antigens
• Progress in protein-based replacement therapies to treat rare disease
• Current opportunities and challenges
Heinrich Haas, VP RNA Formulation & Drug Delivery, BioNTech

Download the brochure and full programme from the event website at www.therapeutics-rna.com/openPR3

RNA Therapeutics
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
ChemGenes | Thermo Fisher Scientific

--- ENDS –

Contact Information:

For media enquiries contact Alia Malick on +44 (0)20 7827 6168

For all delegate enquiries, contact Hakam Panum on +44 (0)20 7827 6128

SMi Group
India House
45 Curlew Street
London
SE1 2ND

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insight into the Latest Developments in Oligonucleotide Delivery Systems here

News-ID: 1857931 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for RNA

CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes. CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the latest research by InsightAce Analytic,
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032. This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through - • 70% efforts of Primary Research • 15% efforts of Secondary Research • 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate? • The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. • Expected exponential
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032. The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may